217 related articles for article (PubMed ID: 31445731)
41. Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.
Zeng L; Xia C; Zhang Y; Yang N
J Thorac Oncol; 2019 Apr; 14(4):e70-e72. PubMed ID: 30922580
[No Abstract] [Full Text] [Related]
42. A novel intergenic region (chr2: 30,193,816)-ALK fusion shows sensitivity to Alectinib in lung adenocarcinoma.
Wang T; Du G; Niu M; Liu R
BMC Pulm Med; 2023 Feb; 23(1):60. PubMed ID: 36755262
[TBL] [Abstract][Full Text] [Related]
43. Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements.
Gao F; Gao F; Wu H; Lu J; Xu Y; Zhao Y
Thorac Cancer; 2022 Apr; 13(7):1088-1090. PubMed ID: 35212154
[TBL] [Abstract][Full Text] [Related]
44. [Ceritinib as First-line Treatment for Advanced Lung Adenocarcinoma
with COX7A2L-ALK Fusion: A Case Report and Literature Review].
Yuan J; Pan R; Zhong W; Wang M
Zhongguo Fei Ai Za Zhi; 2023 Apr; 26(4):319-324. PubMed ID: 37183647
[TBL] [Abstract][Full Text] [Related]
45. Identification of a Novel EML4-ALK, BCL11A-ALK Double-Fusion Variant in Lung Adenocarcinoma Using Next-Generation Sequencing and Response to Crizotinib.
Qin BD; Jiao XD; Liu K; Wu Y; Zang YS
J Thorac Oncol; 2019 Jun; 14(6):e115-e117. PubMed ID: 31122560
[No Abstract] [Full Text] [Related]
46. PLEKHH2-ALK: A Novel In-frame Fusion With Durable Response to Alectinib: Utilizing RNA Sequencing in Search for Hidden Gene Fusions Susceptible to Targeted Therapy.
Nagasaka M; Fisher A; Chowdhury T; Ge Y; Sukari A
Clin Lung Cancer; 2021 Jan; 22(1):e51-e53. PubMed ID: 32893122
[No Abstract] [Full Text] [Related]
47. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
48. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
[TBL] [Abstract][Full Text] [Related]
49. Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment.
Yang X; Li Y; Duan Q; Zhang Q; He M
J Thorac Oncol; 2021 Mar; 16(3):e17-e19. PubMed ID: 33641723
[No Abstract] [Full Text] [Related]
50. Transformation of EML4-ALK fusion-positive adenocarcinoma into squamous cell carcinoma in association with acquired resistance to crizotinib.
Wang F; Qin J; Xie F; Wu Q; Lu H
Lung Cancer; 2020 Feb; 140():118-120. PubMed ID: 31924369
[No Abstract] [Full Text] [Related]
51. Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.
Song P; Zhang J; Shang C; Zhang L
Thorac Cancer; 2018 Oct; 9(10):1327-1332. PubMed ID: 30133144
[TBL] [Abstract][Full Text] [Related]
52. SPECC1L-ALK: A novel gene fusion response to ALK inhibitors in non-small cell lung cancer.
Ma L; Zhang Q; Dong Y; Li H; Wang J
Lung Cancer; 2020 May; 143():97-100. PubMed ID: 32216970
[No Abstract] [Full Text] [Related]
53. Lung adenocarcinoma during pregnancy: clinical case and literature review.
Bellido C; Barbero P; Forcén L; Blanco M; Alonso-Riaño M; Galindo A
J Matern Fetal Neonatal Med; 2019 Oct; 32(19):3300-3302. PubMed ID: 29618241
[TBL] [Abstract][Full Text] [Related]
54. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
55. Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control.
Huang SH; Huang AC; Wang CC; Chang WC; Liu CY; Pavlidis S; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT
Thorac Cancer; 2019 Dec; 10(12):2274-2281. PubMed ID: 31613427
[TBL] [Abstract][Full Text] [Related]
56. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
[TBL] [Abstract][Full Text] [Related]
57. An intergenic region ALK fusion identified by DNA sequencing and validated by IHC in an early-stage lung adenocarcinoma.
Dou Y; Duan Q; Qi C; Hou L; Wang H
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1865-1867. PubMed ID: 33544200
[TBL] [Abstract][Full Text] [Related]
58. Clinical Activity of Crizotinib in Lung Adenocarcinoma Harboring a Rare ZCCHC8-ROS1 Fusion.
Hicks JK; Boyle T; Albacker LA; Madison R; Frampton G; Creelan BC
J Thorac Oncol; 2018 Aug; 13(8):e148-e150. PubMed ID: 30049378
[No Abstract] [Full Text] [Related]
59. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
[TBL] [Abstract][Full Text] [Related]
60. Identification of a novel NPM1-ROS1 fusion in a lung adenocarcinoma and sensitive to crizotinib treatment.
Ma H; Zhang Q; Duan Q; Zhang Q; Li F
Lung Cancer; 2021 Feb; 152():196-198. PubMed ID: 33386152
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]